Firms team up to develop cancer drugs in potential $540M deal

08/6/2013 | Reuters · Genetic Engineering & Biotechnology News

Bayer HealthCare and Compugen signed a preclinical research agreement centered on antibody-based cancer immunotherapies. Bayer will get the rights to further develop and market the drugs arising from the collaboration. The deal entitles Compugen to $10 million upfront and as much as $530 million in milestone fees plus sales royalties.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health